1. Introduction {#s0005}
===============

In recent years, mass spectrometric techniques, including gas chromatography--mass spectrometry (GC/MS) and tandem mass spectrometry (MS/MS), have been used for the biochemical diagnosis of inherited metabolic diseases (IMDs) such as organic acidemias (OAs), fatty acid oxidation disorders (FAODs), and amino acid disorders (AAs). Newborn screening (NBS) for OAs, FAODs, and AAs utilizing MS/MS is becoming popular worldwide and is referred to as expanded NBS (ENBS) \[[@bb0005]\]. The prognoses of patients with diseases targeted by ENBS have markedly improved in countries that have implemented \[[@bb0010], [@bb0015], [@bb0020]\].

Japan introduced nationwide NBS in 1977 and implemented nationwide ENBS in 2014 following a pilot study performed between 1997 and 2012 \[[@bb0025]\]. The latter is also being implemented in other Asian countries, including Taiwan \[[@bb0030]\] and South Korea \[[@bb0035]\]. However, ENBS has yet to be introduced in several other Asian countries in which epidemiological data pertaining to IMDs remain limited \[[@bb0040],[@bb0045]\]. Accordingly, Shimane University has provided biochemical IMD diagnostic services using GC/MS and MS/MS for symptomatic patients (defined as selective screening) from several Asian countries, including Vietnam, China, and India, for \>15 years.

To investigate variations in the incidence rates of IMDs by nation, we investigated the frequencies of OAs, FAODs, and AAs among Asian countries using our selective screening and ENBS records. Furthermore, we compared the detection rates using selective screening and ENBS in Japan with the aim of reevaluating the target diseases of ENBS.

2. Materials & methods {#s0010}
======================

2.1. Selective screening {#s0015}
------------------------

### 2.1.1. Subjects {#s0020}

Screening for IMDs was performed for symptomatic patients upon request by medical institutes in Japan and other Asian countries, including Vietnam, China, India, Indonesia, Thailand, Mongolia, South Korea, Malaysia, Taiwan, and Turkey. The screening was performed using GC/MS and MS/MS at the Department of Pediatrics, Shimane University Faculty of Medicine, Japan between 2000 and 2015. Samples from patients with clinical findings suspected to indicate IMDs, such as metabolic acidosis, ketosis, hyperammonemia, hypoglycemia, lethargy, hypotonia, myopathy-like symptoms, acute encephalopathy, and sudden infant death of unknown cause, were analyzed. If the request included the above symptoms, blood and/or urine samples with the patient\'s data (e.g., clinical course and administered medication) were sent to Shimane University. The frequencies of detected IMDs were retrospectively compared between countries. This study was approved by the Shimane University Institutional Committee on Ethics (registration No. 20170920-2).

### 2.1.2. GC/MS analysis {#s0025}

Urine samples were delivered at room temperature from Asian countries using dried urine filter paper \[[@bb0050]\], whereas frozen urine samples were sent from Japanese medical institutes to Shimane University. The urinary organic acid analysis was conducted as reported previously \[[@bb0050],[@bb0055]\]. A 'GCMS QP-2010 Plus' instrument (Shimadzu, Kyoto, Japan) was used for the analysis.

### 2.1.3. MS/MS analysis {#s0030}

Dried blood filter papers were shipped from overseas at room temperature to Shimane University, as used for ENBS. Blood serum samples from some Japanese patients were analyzed. Only samples from India were analyzed at Fukui University, Japan. Blood acylcarnitines and amino acids were analyzed with MS/MS using in butyl-derivatized specimens \[[@bb0060]\] at both Shimane and Fukui Universities. An API-3000 or API-4000 instrument (Applied Biosystems, Foster City, CA, USA) or an LC/MS/MS-8040 instrument (Shimadzu, Kyoto, Japan) was used for MS/MS.

### 2.1.4. Diagnosis {#s0035}

Biochemical diagnoses were based on the results of GC/MS and/or MS/MS. Data of organic acid analysis were processed using a personal computer-based automated GC/MS data processing and diagnostic system \[[@bb0055]\]. Whereas the diagnoses of nearly all Japanese patients were finally confirmed based on enzyme activity measurements and/or gene mutations, the diagnoses of foreign patients were based on the results of biochemical analyses indicating obvious specific abnormal metabolites in accordance with clinical data (e.g., age, sex, clinical course, laboratory data, and medication use) by several expert physicians who were familiar with IMDs.

2.2. ENBS {#s0040}
---------

To investigate the detection rate of IMDs using ENBS, we obtained nationwide ENBS data from the principal ENBS investigators in Japan, Taiwan, South Korea, and Germany (the latter is a representative European country).

The nationwide ENBS data for each country were acquired as follows. The screening data of approximately 3.36 million infants were screened between 1997 and 2015 in Japan; this population included 1.95 million infants screened during the pilot study period between 1997 and 2012 as described in a domestic journal \[[@bb0025]\] and available data of 1.41 million infants screened from 2013 to 2015. Nationwide ENBS data were not available at least in the period, because ENBS was conducted on a province-by-province basis. Although the annual birth number in Japan was about 1.0 million and the coverage rate was \>99.9%. In Taiwan, approximately 1.39 million babies (coverage rate was \>99.9%; government-funded) participated in ENBS during the period between 2001 and 2014, which included a pilot study conducted from 2001 to 2009 \[[@bb0030]\]. In South Korea, approximately 3.44 million babies (coverage rate was approximately 40 to 80%; paid screening) were screened between 2000 and 2015 as described in a Korean-language domestic report. In Germany, approximately 7.51 million babies (coverage rate was \>99.9%; government-funded) were screened between 2002 and 2015, as described in a domestic report \[[@bb0065]\].

In each country, ENBS was performed according to nationally standardized methods as follows. In Japan, the butyl-derivatization method was used during pilot study; subsequently, a non-derivatized method has been used since at least 2014. In other countries, the butyl-derivatization method was used during the study period, as previously described \[[@bb0020],[@bb0030],[@bb0035]\]. Dried blood spots were collected 4--5 days after birth in Japan, 48--72 h after birth in South Korea and Taiwan, and 36--72 h after birth in Germany.

3. Results {#s0045}
==========

3.1. Selective screening {#s0050}
------------------------

### 3.1.1. Total number of analyzed cases {#s0055}

Among the 39,270 patients analyzed during the study period, 30,625 and 8645 were from Japan and other Asian countries, respectively ([Table 1](#t0005){ref-type="table"}). A total of 58,463 patient samples were analyzed, including 28,469 and 29,994 samples examined using GC/MS and MS/MS, respectively. Of these samples, 43,983 were obtained from Japanese patients and 14,480 were from patients in other Asian countries. Although similar numbers of GC/MS and MS/MS examinations were performed, only the latter type of analysis was requested for patients in whom FAOD was strongly suspected.Table 1Profiles of patients subjected to selective screening.Table 1CountryTotalJapanAsia[a](#tf0005){ref-type="table-fn"}VietnamChinaIndiaIndonesiaThailandMongoliaOthers[b](#tf0010){ref-type="table-fn"}Patients analyzed39,27030,625864530542519210541325124162Samples analyzed58,46343,98314,48060042912413779525730273 GC/MS28,49621,2887181296015292045385919657 MS/MS29,99422,695729930441383209241024810616Cases detected1170377793250216293181231Detection frequency (%)3.01.29.28.28.613.94.44.81.21.6[^1][^2][^3]

Selective screening identified 1170 patients with IMDs, of which 377 and 793 were from Japan and other Asian countries, respectively ([Table 1](#t0005){ref-type="table"}). The overall detection frequency was 3.0% (1.2% in Japan and 9.2% in other Asian countries). The detection frequencies were 8.2%, 8.6%, 13.9%, 4.4%, 4.8%, 1.2%, and 1.6% in Vietnam, China, India, Indonesia, Thailand, Mongolia, and other countries, respectively.

### 3.1.2. Diseases detected using selective screening {#s0060}

The selective screening results are shown in [Table 2](#t0010){ref-type="table"}. Among 377 identified patients with IMDs in Japan, methylmalonic acidemia (MMA) was detected in 81, urea cycle disorders (UCDs) in 60, and glutaric acidemia type II (GA2) in 30. Propionic acidemia (PPA) and multiple carboxylase deficiency (MCD) were each identified in 24 patients. In Vietnam, IMDs were discovered in 250 of the 3054 screened patients; here, maple syrup urine disease (MSUD) was identified in 36, UCDs in 34, β-ketothiolase deficiency (BKTD) in 33, PPA in 22, and 5-oxoprolinemia (OXPA) in 19 patients. In China, IMDs were detected in 216 of the 2519 examined patients; MMA was identified in 94, UCDs in 20, PKU in 18, PPA in 12, and glutaric acidemia type I (GA1) in 10 patients. In India, 293 of the 2105 examined patients were diagnosed with an IMD; the most prevalent diseases were MMA in 72, UCDs in 48, PPA in 26, MSUD in 24, and PKU in 23 patients. In other Asian countries, 34 of the 967 examined patients were diagnosed with IMDs, although no particular diseases were prevalent.Table 2Results of selective screening in Japan and other Asian countries.Table 2CountryJapanVietnamChinaIndiaOthers[a](#tf0015){ref-type="table-fn"}Number of patients37725021629334OA184981401668 Methylmalonic acidemia811294722 Propionic acidemia242212261 MCD242860 Glutaric acidemia type I17110160 MCCD82040 3-methylglutaconic aciduria52131 HMGL deficiency50320 Alkaptonuria50190 4-hydroxybutyric acidemia41200 2-hydroxyglutaric acidemia40141 Isovaleric acidemia26242 β-ketothiolase deficiency2334141 HMGS deficiency20000 5-oxoprolinemia119260FAOD882916105 Glutaric acidemia type II3010822 VLCAD deficiency235330 MCAD deficiency141320 Primary carnitine deficiency138111 CPT2 deficiency64111 TFP/LCHAD deficiency21011AA and UCD741014610811 Phenylketonuria41018233 Maple syrup urine disease2365243 Homocystinuria212343 Urea cycle disorder603420481 Citrin deficiency69091Other diseases31[b](#tf0020){ref-type="table-fn"}20[c](#tf0025){ref-type="table-fn"}14[d](#tf0030){ref-type="table-fn"}9[e](#tf0035){ref-type="table-fn"}10[^4][^5][^6][^7][^8][^9]

3.2. ENBS {#s0065}
---------

### 3.2.1. The incidence of IMDs detected through ENBS {#s0070}

As shown in [Table 3](#t0015){ref-type="table"}, the overall IMD detection incidences with ENBS were 1:8557 in Japan, 1:7030 in Taiwan, 1:13,205 in South Korea, and 1:2200 in Germany. In Japan, diseases with higher incidences included PPA (1:41,000), PKU (1:46,000), very-long chain acyl-CoA dehydrogenase (VLCAD) deficiency (1:93,000), citrin deficiency (1:96,000), MMA (1:120,000), and medium-chain acyl-CoA dehydrogenase (MCAD) deficiency (1:129000). In Taiwan, 3-methylcrotonyl-CoA carboxylase deficiency (MCCD) was most frequently detected (1:41,000), followed by PKU (1:58,000), citrin deficiency (1:61,000), primary carnitine deficiency (PCD) (1:70,000), and MMA, GA1, and MSUD (1:107,000 each). In South Korea, MCCD was the most commonly identified disorder (1:111,000), followed by citrulinemia type I (CTLN1) (1:115000), tyrosinemia type I (1:123,000), isovaleric acidemia and PKU (1:138,000 each), and MMA (1:246,000). In Germany, PKU (1:5000) was most frequently detected, followed by MCAD deficiency (1:10,000), CTLN1 (1:60,000), MCCD (1:73,000), and VLCAD deficiency (1:76,000).Table 3Comparison of expanded newborn screening detection incidences of IMDs per country.Table 3CountryJapan^⁎^[a](#tf0040){ref-type="table-fn"}Taiwan^⁎^[b](#tf0045){ref-type="table-fn"}Korea^⁎^[c](#tf0050){ref-type="table-fn"}Germany^⁎^[d](#tf0055){ref-type="table-fn"}Total No. of newborns screened3.36 million1.39 million3.44 million7.51 millionTotal detection incidence1:85571:70301:13,2051:2200OA1:22,0001:18,0001:31,0001:10,000 Methylmalonic acidemia1:120,0001:107,0001:246,0001:125000 Propionic acidemia1:41,0001:464,0001:313,0001:250,000 Isovaleric acidemia1:672,0001:696,0001:138,0001:96,000 MCD1:1,121,0001:464,000n.a.0 MCCD1:153,0001:41,0001:111,0001:73,000 HMGL deficiency0n.a.1:861,0001:550,000 Glutaric acidemia type I1:280,0001:107,0001:492,0001:127,000 β-ketothiolase deficiency0n.a.n.a.0FAOD1:30,0001:34,0001:111,0001:9000 CPT1 deficiency1:420,0001:696,000n.a.1:1,020,000 VLCAD deficiency1:93,0001:1,392,0001:383,0001:76,000 MCAD deficiency1:1290001:350,0001:492,0001:10,000 TFP/LCHAD deficiency1:840,000n.a.1:1,148,0001:176,000 CPT2 deficiency1:257,0001:696,000n.a.1:3,060,000 CACT deficiency0n.a.n.a.1:7,510,000 GA21:480,0001:696,000n.a.1:195000 Primary carnitine deficiency1:1990001:70,0001:3450001:250,000 HAD deficiency1:3,363,000n.a.1:1,723,0000AA and UCD1:26,0001:17,0001:290001:5000 Phenylketonuria1:46,0001:58,0001:138,0001:5000 Maple syrup urine disease1:841,0001:107,0001:1,148,0001:164,000 Homocystinuria1:1120,000n.a.1:492,0001:132,000 Tyrosinemia type I0n.a.1:123,0001:150,000 Citrullinemia type I1:306,0001:1990001:1150001:60,000 Argininosuccinic aciduria1:1121,0001:593,0001:1,148,0001:292,000 Citrin deficiency1:96,0001:61,0001:3,445,0000[^10][^11][^12][^13][^14]

### 3.2.2. Comparison of selective screening and ENBS in Japan {#s0075}

According to selective screening, MMA was the most frequently identified disorder in Japan, occurring in 81 (50.9%) of all 163 patients with OA, followed by PPA and MCD (14.7% each) ([Table 4](#t0020){ref-type="table"}). In contrast, ENBS identified PPA as the most frequently diagnosed disorder, occurring in 82 (53.9%) of all 152 patients with OAs, followed by MMA (18.4%), and MCCD (14.5%). MCD was identified in only 2.0% of patients.Table 4Comparison of the results of selective screening and expanded newborn screening in Japan.Table 4Selective screeningENBSCases diagnosed377393OA163 (100%)152 (100%) Methylmalonic acidemia[81 (50.9)]{.ul}28 (18.4) Propionic acidemia24 (14.7)[82 (53.9)]{.ul} Isovaleric acidemia2 (1.2)5 (3.3) MCD[24 (14.7)]{.ul}3 (2.0) MCCD8 (4.9)22 (14.5) HMGL deficiency5 (3.1)0 Glutaric acidemia type I17 (10.4)12 (3.1) β-ketothiolase deficiency2 (1.2)0FAOD88 (100%)112 (100%) CPT1 deficiency08 (7.1) VLCAD deficiency23 (26.1)36 (32.1) MCAD deficiency14 (15.9)[26 (23.2)]{.ul} TFP/LCHAD deficiency2 (2.3)4 (3.6) CPT2 deficiency6 (6.8)13 (11.6) GA2[30 (34.1)]{.ul}7 (6.3) Primary carnitine deficiency13 (14.8)17 (15.2) HAD deficiency01 (0,9)AA22 (100%)129 (100%) Phenylketonuria4 (18.8)[73 (56.5)]{.ul} Maple syrup urine disease2 (9.1)4 (3.1) Homocystinuria2 (9.1)3 (2.3) Citrullinemia type I6 (27.3)11 (8.5) Argininosuccinic aciduria2 (9.1)3 (2.3) Citrin deficiency6 (27.3)35 (27.1)[^15][^16][^17]

Among patients with FAODs, GA2 was the most frequently identified by selective screening (30 of all 88 patients with FAODs, or 34.1%), followed by VLCAD deficiency (26.1%), MCAD deficiency (15.9%), and PCD (14.8%). In contrast, ENBS most frequently detected VLCAD deficiency (36 of 112 patients with FAODs, 32.1%), followed by MCAD deficiency (23.2%), PCD (15.2%), and carnitine palmitoyltransferase II deficiency (11.6%).

Among patients with AA, CTLN1 and citrin deficiency were most frequently discovered via selective screening (27.3% of all AA patients each). Although PKU was identified in only 4 patients upon symptomatic screening, it was the most commonly detected disorder by ENBS (73 of 129 patients, 56.5%).

4. Discussion {#s0080}
=============

Our study revealed differences in the incidence of IMDs among Asian countries; these differences were observed when using selective screening and ENBS (including when compared with a European country-- Germany -- using the latter). Furthermore, the IMD frequencies and spectra revealed by selective screening differed from those identified by ENBS.

Notably, selective screening and ENBS demonstrated unique characteristics regarding the incidence of OAs in each country. Although MMA was frequently detected in several countries, a high number of patients with PPA was detected in Japan; this can be attributed to a common Japanese-specific mutation (p.Y435C) of *PCCB* \[[@bb0070],[@bb0075]\], which is generally associated with mild phenotypes and unlikely to be detected during selective screening. Compared to other Asian countries, BKTD and OXPA were more frequent in Vietnam, while MMA was more frequent in China. The high incidence of BKTD in the Vietnamese population can be attributed to a common Vietnamese-specific *ACAT1* mutation (p.R208X) \[[@bb0080]\]. OXPA was also frequently detected in this study, and many patients presented with typical symptoms of glutathione synthetase deficiency, such as chronic metabolic acidosis and hemolytic anemia. However, data on the genetic etiology of OXPA are presently unavailable, and further consideration will be needed.

The high incidence of MMA in China as detected via ENBS is consistent with previous reports \[[@bb0085], [@bb0090], [@bb0095]\] and might be attributable to a common Chinese population-specific *MMACHC* mutation (p.W203X) \[[@bb0100],[@bb0105]\]. Patients with this type of MMA develop homocystinuria (HCU) consequent to a *Cbl* C defect. Although MMA-like disease caused by vitamin B12 deficiency is well-known in South Asian countries such as Nepal and India, no Chinese patients with MMA caused by dietary vitamin B12 deficiency were identified in our study, possibly because of the lack of cases involving episodes and histories indicating a dietary vitamin B12 deficiency (e.g., megaloblastic anemia and gastro resection). Although MMA, PPA, and BKTD were also frequently detected in India, the reasons for these relatively higher frequencies are currently unknown. Several Indian research institutes are now conducting pilot studies on ENBS \[[@bb0110],[@bb0115]\], which may clarify the genetic backgrounds of these OAs.

Regarding FAODs, GA2, VLCAD deficiency, MCAD deficiency, and PCD were frequently detected during the selective screening of Japanese children, whereas GA2 was relatively common in other Asian countries. Using ENBS, the incidence rate of MCAD deficiency detected in Germany was 1:10,000, which is over 10-fold higher than that of Japanese patients. Approximately 90% of the mutant alleles of *ACADM* in Caucasian patients with MCAD deficiency are known to harbor a common variant (p.K329E) \[[@bb0120]\], and the p.Y67H mutation of *ACADM* has been identified in asymptomatic European patients \[[@bb0125]\]. In Asian countries, MCAD deficiency was more frequent in Japan than in Taiwan and South Korea and was associated with the common *ACADM* mutation p.T150Rfs (c.449-452delCTGA), which is found in 30--40% of mutant alleles in Japanese patients with MCAD deficiency \[[@bb0130],[@bb0135]\]. This mutation was also reported in some patients from South Korea \[[@bb0140]\]. Hence, further studies in other Asian countries and beyond should clarify the genetic background of MCAD deficiency.

Regarding AAs, the frequencies of PKU, MSUD, and UCDs identified by selective screening were greater in other Asian countries than in Japan. MSUD was particularly common in Vietnam and India, suggesting that this condition may be prevalent in southeastern Asian countries. In contrast, the numbers of Japanese patients with PKU, MSUD, and HCU detected via selective screening were very small. These diseases are already included in Japanese NBS panels, and therefore are not normally requested during selective screening. PKU and citrin deficiency were detected relatively frequently during ENBS in Japan and Taiwan. Citrin deficiency is considered more prevalent in East Asian countries \[[@bb0145]\]. Notably, the incidence of PKU in Germany was 10-fold higher than that in Japan and Taiwan. These findings suggest that the incidence rates of AAs differ between European and Asian populations.

A comparison of IMD detection rates in Japan via selective screening versus ENBS revealed different disease frequencies per screening method. PPA, MCCD, VLCAD deficiency, MCAD deficiency, PKU, and citrin deficiency were discovered more frequently with ENBS than with selective screening. In particular, PPA was less frequently identified by selective screening than by ENBS. On the other hand, a larger number of patients with MCD were identified via selective screening, whereas very few were discovered with ENBS. Of the 24 Japanese patients with MCD, at least 7 were diagnosed with MCD secondary to dietary biotin insufficiency, which might have contributed to the large number of MCDs identified via selective screening. Moreover, a Japanese group first reported the cloning of the *HCS* gene, which encodes holocarboxylase synthetase, and the discovery of a mutation contributing to the underlying etiology of MCD \[[@bb0150],[@bb0155]\]. This discovery may have raised awareness of MCD along with its characteristic clinical features among practicing physicians in Japan. However, the actual MCD detection rate with ENBS was likely very low. Moreover, biotinidase deficiency has not been observed in the Japanese population.

This study had several limitations of note. During selective screening, the diagnoses of most patients were based mainly on the results of biochemical analysis. Because we did not examine genetic factors or enzyme activities, we could not conclude whether the incidence of each IMD was influenced by the genetic background or by other causes (e.g., dietary vitamin B12 and biotin deficiencies or the intakes of some drugs). Indeed, it may be difficult to prove that the high prevalence rates of some diseases could be attributed solely to population-specific common mutations. Furthermore, it might be difficult to completely compare the results of selective screening with those of ENBS. Nevertheless, the observed differences in incidence rates from before to after the implementation of ENBS will help other Asian countries to determine which diseases should be included in ENBS panels.

During the last 40 years, NBS has played an important role in preventing neurological impairment by detecting diseases such as PKU in the pre-symptomatic phase. Although this is also true for ENBS \[[@bb0005],[@bb0010],[@bb0020]\], ENBS can also detect diseases that may not require treatment, such as mild PPA or asymptomatic VLCAD deficiency, which are relatively common in Japan and Europe \[[@bb0015]\]. Although no previous report has described symptoms among patients with mild PPA, the evidence that these patients remain asymptomatic throughout their lives has not yet reported. Therefore, we cannot conclude whether mild PA should or should not be excluded from screening at the present point. Our results, however, suggest that such diseases could potentially be excluded in the future after determining the natural disease history. Additionally, the diseases targeted by ENBS may be amended to reflect the individual country. Finally, the target diseases identified by ENBS are generally extremely rare. Therefore, international collaborative activities such as the current study are important to the clarification of the natural histories of these diseases, development of diagnostic methods and therapies, and elucidation of genetic backgrounds.

5. Conclusion {#s0085}
=============

Our study identified diverse IMD incidence rates and disease spectra among Asian countries. The IMD disease spectra determined by selective screening differed from those detected by ENBS. These data may facilitate improvements in ENBS implementation, the development of diagnostic and therapeutic groundwork, and the enhancement of welfare policies (including reductions in screening costs).
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[^1]: GC/MS, gas chromatography--mass spectrometry; MS/MS, tandem mass spectrometry.

[^2]: "Asia" indicates Asian countries other than Japan.

[^3]: "Others" includes 38 patients from South Korea, 16 from Malaysia, 6 from Taiwan, and 2 from Turkey.

[^4]: OA, organic acidemia; MCD, multiple carboxylase deficiency; MCCD, 3-methylcrotonyl-CoA carboxylase deficiency; HMGL, 3-hydroxy-3-methylglutaryl-CoA lyase; HMGS, 3-hydroxy-3-methylglutaryl-CoA synthetase; FAOD, fatty acid oxidation disorder; VLCAD, very long-chain acyl-CoA dehydrogenase, MCAD, medium-chain acyl-CoA dehydrogenase; CPT2, carnitine palmitoyltransferase II; TFP, trifunctional protein; LCHAD, long-chain 3-hydroxyacyl-CoA dehydrogenase; AA, amino acid disorder; UCD, urea cycle disorder.

[^5]: "Other countries" includes 18 patients from Indonesia, 12 from Thailand, 3 from Mongolia, and 1 from Malaysia.

[^6]: Thirty-one patients in Japan with other diseases included 16 strongly suspected of FAOD with non-ketotic dicarboxylic aciduria, 10 with peroxisomal diseases, and 4 with other diseases.

[^7]: Twenty patients with other diseases in Vietnam included 16 strongly suspected of having FAOD with non-ketotic dicarboxylic aciduria, 2 with peroxisomal diseases, and 1 each with carnitine palmitoyltransferase I (CPT1) deficiency and short-chain acyl-CoA dehydrogenase deficiency (SCAD) deficiency.

[^8]: Fourteen patients with other diseases in China included 9 suspected of having FAOD with non-ketotic dicarboxylic aciduria, 2 with SCAD deficiency, and 1 each with CPT1 deficiency, mevalonic acidemia, and tyrosinemia type I.

[^9]: Nine patients from India with other diseases included 3 strongly suspected of having FAOD with non-ketotic dicarboxylic aciduria, 4 with tyrosinemia type I, and 1 each with ethylmalonic encephalopathy and 3-hydoxyacyl-CoA dehydrogenase deficiency.

[^10]: OA, organic acidemia; MCD, multiple carboxylase deficiency; MCCD, 3-methylcrotonyl-CoA carboxylase deficiency; HMGL, 3-hydroxy-3-methylglutaryl-CoA lyase; FAOD, fatty acid oxidation disorder; CPT1, carnitine palmitoyltransferase I; VLCAD, very long-chain acyl-CoA dehydrogenase, MCAD, medium-chain acyl-CoA dehydrogenase; TFP, trifunctional protein; LCHAD, long-chain 3-hydroxyacyl-CoA dehydrogenase; CPT2, carnitine palmitoyltransferase II; CACT, carnitine-acylcarnitine translocase; GA2, glutaric acidemia type II; HAD, 3-hydoxyacyl-CoA dehydrogenase; AA, amino acid disorder; UCD, urea cycle disorder; n.a., not available.

[^11]: Data from Japan are from 1997 to 2015.

[^12]: Data from Taiwan are from 2001 to 2014.

[^13]: Data from Korea are from 2000 to 2015.

[^14]: Data from Germany are from 2002 to 2015.

[^15]: (%) percentage of each group disease.

[^16]: Selective screening was performed at Shimane University. Newborn screening was performed across Japan during the period from 1997 to 2015, as described in the text. Underlined values indicate the diseases in which large differences in incidence were observed between symptomatic screening and ENBS.

[^17]: OA, organic acidemia; MCD, multiple carboxylase deficiency; MCCD, 3-methylcrotonyl-CoA carboxylase deficiency; HMGL, 3-hydroxy-3-methylglutaryl-CoA lyase; FAOD, fatty acid oxidation disorder; CPT1, carnitine palmitoyltransferase I; VLCAD, very long-chain acyl-CoA dehydrogenase, MCAD, medium-chain acyl-CoA dehydrogenase; TFP, trifunctional protein; LCHAD, long-chain 3-hydroxyacyl-CoA dehydrogenase; CPT2, carnitine palmitoyltransferase II; GA2, glutaric acidemia type II; HAD, 3-hydoxyacyl-CoA dehydrogenase; AA, amino acid disorder.
